User Tools

Site Tools


medulloblastoma

Medulloblastoma

Medulloblastomas are small cell embryonal tumors of the cerebellum.

Epidemiology

Classification

Etiology

Several lines of evidence implicate granule neuron precursors (GNP) in the external granule layer (EGL) of the developing cerebellum as likely cells of origin for certain classes of medulloblastomas.

1). For example, cells that compose a preneoplastic stage of medulloblastoma colocalize with GNPs in the EGL and they express molecular markers of immature granule neurons ( 2). Another possible medulloblastoma cell of origin has been identified: a neural progenitor located in the cerebellar white matter and expressing both nestin and prominin ( 3). Signal transduction pathways that stimulate proliferation and inhibit differentiation of GNPs and other neural progenitor cells during development have been implicated in medulloblastoma. Thus, understanding the mitogenic functions of these pathways will yield insights into medulloblastoma formation.

The overexpression of proteins that normally stimulate proliferation of neural progenitor cells may initiate medulloblastoma formation. Two known mitogens for neural progenitors are the c-Myc oncoprotein and Sonic hedgehog (Shh), a crucial determinant of embryonic pattern formation in the central nervous system.

Several genes have been implicated in the development of medulloblastoma in children, including Patched-1 and Smoothened. The protein products of these genes function within the sonic hedgehog molecular signaling pathways, which are important in neural development and disease.

Pathogenesis

Medulloblastoma, occurs with increased frequency in individuals with Fanconi anemia who have biallelic germline mutations in BRCA2.

Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells 1).

Combined activation of the Shh/Ptc and IGF signaling pathways is an important mechanism in MB pathogenesis 2).

Both pathways are essential regulators of granule neuron precursors (GNP) proliferation during cerebellar development. In cultured GNPs, IGF signaling stabilizes the oncogenic transcription factor N-myc by inhibiting glycogen synthase kinase 3beta-dependent phosphorylation and consequent degradation of N-myc. However, determinants of Shh and IGF tumorigenicity in vivo remain unknown

Activation of the Sonic hedgehog (Shh)/Patched signaling pathway in the postnatal cerebellum is sufficient to induce medulloblastoma in mice. Activation of the phosphatidylinositol 3-kinase (PI3K) signaling pathway by insulin-like growth factor-II, inactivation of the p53 tumor suppressor protein, loss of DNA damage repair mechanisms, and ectopic expression of Myc oncoproteins cooperate with Shh/Patched signaling to enhance tumor formation in mice. Ectopic expression of alpha and beta interferons in the developing brain also induces Shh-mediated medulloblastoma formation, suggesting a possible role for antiviral response in the genesis of medulloblastoma 3).

Clinical features

May also cause nuclear facial palsy (from the involvement of facial colliculus on the floor of the fourth ventricle).

Dissemination

Cerebrospinal fluid (CSF) dissemination to the cranio-spinal axis occurs in 30% to 40% of cases 4).

However, medulloblastoma primarily presenting with symptoms related to spinal metastasis is extremely rare 5) 6).

To date, there are only a limited number of cases that have been reported in the literature 7) 8) 9).

Pathology

Molecular biology

Diagnosis

Differential diagnosis

Ewing's Sarcoma peripheral primitive neuroectodermal tumor

Fourth ventricle ependymoma:

Usually arises from the floor of the 4th ventricle

Typically squeezes out the foramen of Luschka.

Chen et al. encountered a patient with medulloblastoma in which the neuroimaging findings mimicked those of dysplastic cerebellar gangliocytoma. In patients with a posterior fossa tumor suggestive of a dysplastic gangliocytoma on neuroimaging studies, a pathologic confirmation is necessary 10).

Treatment

Complications

Hydrocephalus.

Obstructive hydrocephalus by blocking CSF pathways around the aqueduct. Extraneural metastases is probably a relatively low risk of cerebrospinal fluid shunt 11). A tumor filter may eventually become occluded by tumor cells and need replacement; may be able to radiate tumor filter to “sterilize” it 12).

Outcome

Response Assessment

Lack of standard response criteria in clinical trials for medulloblastoma and other seeding tumors complicates assessment of therapeutic efficacy and comparisons across studies. An international working group was established to develop consensus recommendations for response assessment. The aim is that these recommendations be prospectively evaluated in clinical trials, with the goal of achieving more reliable risk stratification and uniformity across clinical trials. Current practices and literature review were performed to identify major confounding issues and justify subsequently developed recommendations; in areas lacking scientific investigations, recommendations were based on experience of committee members and consensus was reached after discussion. Recommendations apply to both adult and pediatric patients with medulloblastoma and other seeding tumors. Response should be assessed using MR imaging (brain and spine), Cerebrospinal fluid cytology, and neurologic examination. Clinical imaging standards with minimum mandatory sequence acquisition that optimizes detection of leptomeningeal metastases are defined.

Warren et al. recommend central review prior to inclusion in treatment cohorts to ensure appropriate risk stratification and cohort inclusion. Consensus recommendations and response definitions for patients with medulloblastomas and other seeding tumors have been established; as with other RANO recommendations, these need to now be prospectively validated in clinical trials 13).

Case series

Case reports

A 63-year-old woman with an atypical medulloblastoma in the cerebellum and a lesion in the suprasellar area that did not appear to be a metastasis of the medulloblastoma. The patient underwent a subtotal resection of the cerebellar medulloblastoma which was classified histologically as classic subtype and molecularly as non-WNT/non-Sonic hedgehog (SHH) subtype in the World Health Organization Classification of Tumors of the Central Nervous System 2016. Then she underwent postoperative chemotherapy followed by radiotherapy. We administered chemotherapy to facilitate therapeutic diagnosis of the suprasellar lesion. The combination treatment resulted in the disappearance of the cerebellar medulloblastoma with treatment toxicity well tolerated, additionally the suprasellar lesion remains under control.

Even in adults over 60 years of age, medulloblastoma should be included in the differential diagnosis of a cerebellar mass, and chemotherapy for adult medulloblastoma has the potential to be efficacious and tolerable 14).

References

1)
Maurer AJ, Bonney PA, Toho LC, Glenn CA, Agarwal S, Battiste JD, Fung KM, Sughrue ME. Tumor necrosis-initiated complement activation stimulates proliferation of medulloblastoma cells. Inflamm Res. 2015 Jan 22. [Epub ahead of print] PubMed PMID: 25603857.
2)
Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene. 2004 Aug 12;23(36):6156-62. PubMed PMID: 15195141.
3)
Fults DW. Modeling medulloblastoma with genetically engineered mice. Neurosurg Focus. 2005 Nov 15;19(5):E7. Review. PubMed PMID: 16398471.
4) , 5) , 8)
Park TS, Hoffman HJ, Hendrick EB, Humphreys RP, Becker LE. Medulloblastoma: clinical presentation and management. Experience at the hospital for sick children, Toronto, 1950-1980. J Neurosurg. 1983;58:543–552. doi: 10.3171/jns.1983.58.4.0543.
6)
Laurent JP. Brain tumors in children. J Pediatr Neurosci. 1985;1:15–32.
7)
Allen JC. Childhood brain tumors: current status of clinical trials in newly diagnosed and recurrent disease. Pediatr Clin North Am. 1985;32:633–651.
9)
Stanley P, Suminski N. The incidence and distribution of spinal metastases in children with posterior fossa medulloblastomas. Am J Pediatr Hematol Oncol. 1988;10:283–287. doi: 10.1097/00043426-198824000-00002.
10)
Chen KS, Hung PC, Wang HS, Jung SM, Ng SH. Medulloblastoma or cerebellar dysplastic gangliocytoma (Lhermitte-Duclos disease)? Pediatr Neurol. 2002 Nov;27(5):404-6. PubMed PMID: 12504212.
11)
Berger MS, Baumeister B, Geyer JR, Milstein J, et al. The Risks of Metastases from Shunting in Children with Primary Central Nervous System Tumors. J Neurosurg. 1991; 74:872–877
12)
Kessler LA, Dugan P, Concannon JP. Systemic Metastases of Medulloblastoma Promoted by Shunting. Surg Neurol. 1975; 3:147–152
13)
Warren KE, Vezina G, Poussaint TY, Warmuth-Metz M, Chamberlain MC, Packer RJ, Brandes AA, Reiss M, Goldman S, Fisher MJ, Pollack IF, Prados MD, Wen PY, Chang SM, Dufour C, Zurakowski D, Kortmann RD, Kieran MW. Response Assessment in Medulloblastoma and Leptomeningeal Seeding Tumors: Recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee. Neuro Oncol. 2017 Apr 25. doi: 10.1093/neuonc/nox087. [Epub ahead of print] PubMed PMID: 28449033.
14)
Murase M, Saito K, Abiko T, Yoshida K, Tomita H. Medulloblastoma in Older Adults: A Case Report and Literature Review. World Neurosurg. 2018 Jun 5. pii: S1878-8750(18)31170-7. doi: 10.1016/j.wneu.2018.05.216. [Epub ahead of print] PubMed PMID: 29883827.
medulloblastoma.txt · Last modified: 2019/09/05 20:31 by administrador